Pharmaceutical development and preclinical studies of the drug revinorm

The aim of the research was the pharmaceutical development of a complex drug for the treatment of acute heat stress in cattle and the implementation of its preclinical studies (acute and chronic toxicity, local irritant effect). The conducted studies made it possible to determine the rational composition and carry out the pharmaceutical development of the complex drug revinorm. Based on preclinical studies, it has been shown that revinorm belongs to low-hazard substances (hazard class IV according to GOST 12.1.007-76 “Harmful substances”), with long-term use it is harmless to warmblooded animals, and also does not exhibit a local irritant effect.